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1. INTRODUCTION {#jcb29167-sec-0010}
===============

Compared to gastric cancer, adenocarcinoma of the esophagogastric junction (AEG) is a special type of carcinoma. AEG involves both distal esophageal and proximal gastric adenocarcinoma. Some evidences demonstrate that AEG is unlike distal gastric adenocarcinoma in tumor evolution, molecular characteristics, and biology behavior.[1](#jcb29167-bib-0001){ref-type="ref"} The incidence of AEG is rapidly increasing in East Asia, Europe, and North America over the last two decades.[2](#jcb29167-bib-0002){ref-type="ref"}, [3](#jcb29167-bib-0003){ref-type="ref"}, [4](#jcb29167-bib-0004){ref-type="ref"} The occurrence and progress of AEG are unknown. It is assumed that the increasing of AEG may be associated with the elevated ratio of obesity and overweight.[5](#jcb29167-bib-0005){ref-type="ref"} It is estimated that the 5‐year survival rate of AEG is only 10 to 15%.[6](#jcb29167-bib-0006){ref-type="ref"} Revealing novel cancer markers are helpful to improve the diagnosis and prognosis of patients with AEG.

The transcription factor 7‐like 2 (TCF7L2) is a functional transcription factor, which locates on the long arm of chromosome 10q25.2‐q25.3. TCF7L2 is a member of the high mobility group box family.[7](#jcb29167-bib-0007){ref-type="ref"} The TCF7L2 protein might be implicated in regulating Wnt/β‐catenin signaling pathway,[8](#jcb29167-bib-0008){ref-type="ref"}, [9](#jcb29167-bib-0009){ref-type="ref"}, therefore, it could be associated with the etiology of malignancy. Chen et al[10](#jcb29167-bib-0010){ref-type="ref"} reported that frequent TCF7L2 overexpression was identified in both primary and metastatic gastric cancer. Ishiguro et al[11](#jcb29167-bib-0011){ref-type="ref"} also reported that expression of TCF7L2 in esophageal squamous cell carcinoma might be correlated with a poor prognosis. There are many single‐nucleotide polymorphisms (SNPs) in *TCF7L2* gene identified in the past investigations (<https://www.ncbi.nlm.nih.gov/snp/?term=TCF7L2>). The rs7903146 and rs290481 polymorphisms were two of the most widely explored SNPs in *TCF7L2* gene. Previous studies demonstrated that *TCF7L2* rs7903146 polymorphism conferred the susceptibility to breast cancer.[12](#jcb29167-bib-0012){ref-type="ref"}, [13](#jcb29167-bib-0013){ref-type="ref"} Ling et al[14](#jcb29167-bib-0014){ref-type="ref"} found that *TCF7L2* rs290481 T \> C had a tendency of risk to hepatocellular carcinoma (HCC). However, the association of *TCF7L2* SNPs with the risk of AEG remains unknown.

Recently, it is found that both cancer and diabetes have increased the prevalence and many malignancies are attributable to obesity and overweight‐related diseases.[15](#jcb29167-bib-0015){ref-type="ref"} Evidence indicated that excess insulin (INS) might favor tumor.[16](#jcb29167-bib-0016){ref-type="ref"} Cancer promotion mechanisms of hyperinsulinemia have been expounded in previous in vitro studies. Insulin receptor (INSR) is overexpressed in most tumor tissues compared to normal tissues.[17](#jcb29167-bib-0017){ref-type="ref"} Cancer cells may be more keen to the role of INS. Approximately 20% of patients with breast cancer have an over 10‐fold INSR expression than normal tissue.[18](#jcb29167-bib-0018){ref-type="ref"} A shorter INSR‐A isoform (INSR‐A) is expressed in cancer cells. However, INSR‐B is a dominant form in INS target tissues (eg liver, adipose, and muscle etc) and significantly affect metabolic activity. Compared to INSR‐B, the INSR‐A has an increased mitogenic effect and binds both insulin‐like growth factor‐2 and INS with high affinity.[19](#jcb29167-bib-0019){ref-type="ref"}, [20](#jcb29167-bib-0020){ref-type="ref"} Previous study has shown that *INS* rs689 was associated with the risk of polycystic ovary syndrome,[21](#jcb29167-bib-0021){ref-type="ref"} and there was a study indicated that *INSR* rs1799817 was related to the occurrence of type 2 diabetes (T2D). Mahmoudi et al[22](#jcb29167-bib-0022){ref-type="ref"} reported that the *INSR* rs1799817 was a risk factor to CRC among women. But, so far, there was no investigation focused on the relationship between *INS* rs689 and *INSR* rs1799817 and AEG risk.

In this study, we selected *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 and explored the association of these SNPs with AEG.

2. MATERIALS AND METHODS {#jcb29167-sec-0020}
========================

2.1. Subjects {#jcb29167-sec-0030}
-------------

This study involved 720 patients with AEG and 1541 healthy controls. All AEG cases were diagnosed by gastroscope and pathology. The healthy controls matched to patients with AEG by ethnicity, sex, and age. A total of 1541 controls was recruited. The detailed information of the participants was present in our previous study.[23](#jcb29167-bib-0023){ref-type="ref"} Each participant was informed of the study purpose and signed a written informed consent. In this study, a questionnaire was used to collect demographic data (sex and age), smoking, and drinking history. In addition, body mass index (BMI) ≥24 kg/m^2^ was used as the criterion for overweight and obesity.[24](#jcb29167-bib-0024){ref-type="ref"}, [25](#jcb29167-bib-0025){ref-type="ref"} This study protocol was approved by the ethical committees of Jiangsu University.

2.2. DNA extraction and stored {#jcb29167-sec-0040}
------------------------------

Each individual donated a venous blood sample with ethylenediaminetetraacetic acid anticoagulant, which was stored in a refrigerator at −80°C. The genomic DNA from whole blood was carefully extracted by using a Promega DNA Purification Kit (Promega, Madison).

2.3. *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms genotype {#jcb29167-sec-0050}
---------------------------------------------------------------------------------------------

*TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 SNPs were genotyped by SNPscan genotyping assay (Genesky Biotechologies Inc, Shanghai, China). To perform quality control, we randomly selected 90 DNA samples. The genotypes of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 were tested by another research assistant. The reproducibility was 100%.

2.4. Statistical analysis {#jcb29167-sec-0060}
-------------------------

SAS software (Version 9.4; SAS Institute Inc, Cary, NC) was used to conduct data analysis. All genotypic distributions were checked whether the distribution of genotype frequencies was in Hardy--Weinberg equilibrium by using an internet‐based software ([http://ihg.gsf.de/cgi‐bin/hw/hwa1.pl](http://ihg.gsf.de/cgi-bin/hw/hwa1.pl)). Mean age, weight, height, and BMI were expressed as the mean ± standard deviation (SD). The Student *t* test was used to compare continuous variables. Statistical significance of genotypes between two groups was assessed by using Fisher\'s exact/Chi‐square (χ^2^) test, crude/adjusted odds ratio, and 95% confidence interval (95%). A *P* \< .05 was considered as statistical significance.

3. RESULTS {#jcb29167-sec-0070}
==========

3.1. Baseline characteristics {#jcb29167-sec-0080}
-----------------------------

The selected risk factors and demographics of participants are listed in Table [1](#jcb29167-tbl-0001){ref-type="table"}. In our study, 720 patients with AEG were enrolled. Among the patients, 532 were males (73.89%) and 188 were females (26.11%). In case group, the mean age and SD was 64.21 ± 8.82 years. There were 424 patients (58.89%) with lymphatic metastasis and 296 patients without lymphatic metastasis (41.11%). The patients with AEG included 211 cases with stage I/II and 509 with stage III/IV disease. Two authors reviewed the clinical data and assessed the disease stage by using the AJCC version 7.0 criteria (2010). For controls, we recruited 1541 cancer‐free individuals, 1137 males (73.78%), and 404 females (26.22%). Their age mean ± SD was 64.30 ± 10.19 years. Age and sex were full‐matched. We found that there were significant differences in the distribution of smoking, drinking status, and BMI among the two groups. Table [2](#jcb29167-tbl-0002){ref-type="table"} lists the primary information of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms.

###### 

Distribution of selected demographic variables and risk factors in AEG cases and controls

  Variable                Overall cases (n = 720)   Overall controls (n = 1541)   *P* [^a^](#jcb29167-tbl1-note-0002){ref-type="fn"}
  ----------------------- ------------------------- ----------------------------- ----------------------------------------------------
  Age, y, M ± SD          64.21 ± 8.82              64.30 ± 10.19                 .826
  Age, y                                                                          .312
  \<64, n (%)             327 (45.42)               735 (47.70)                   
  ≥64, n (%)              393 (54.58)               806 (52.30)                   
  Sex                                                                             .958
  Male, n (%)             532 (73.89)               1137 (73.78)                  
  Female, n (%)           188 (26.11)               404 (26.22)                   
  Smoking                                                                         **.015**
  Never, n (%)            525 (72.92)               1196 (77.61)                  
  Ever, n (%)             195 (27.08)               345 (22.39)                   
  Drinking                                                                        **.001**
  Never, n (%)            608 (84.44)               1377 (89.36)                  
  Ever, n (%)             112 (15.56)               164 (10.64)                   
  Height (cm), M ± SD     164.8 ( ± 7.28)           166.2 ( ± 7.21)               **\<.001**
  Weight (kg), M ± SD     61.98 ( ± 10.35)          65.94 ( ± 9.78)               **\<.001**
  BMI (kg/m^2^), M ± SD   22.77 ( ± 3.13)           23.85 ( ± 2.96)               **\<.001**
  BMI (kg/m^2^)                                                                   
  \<24, n (%)             476 (66.11)               827 (53.67)                   **\<.001**
  ≥24, n (%)              244 (33.89)               714 (46.33)                   
  Lymph node status                                                               
  Positive, n (%)         424 (58.89)                                             
  Negative, n (%)         296 (41.11)                                             
  AJCC TMN stage                                                                  
  I + II, n (%)           211 (29.31)                                             
  III + IV, n (%)         509 (70.69)                                             

*Note*: Bold values are statistically significant (*P*\< .05). Abbreviations: AJCC, American Joint Committee on Cancer; AEG, esophagogastric junction; BMI, body mass index; M ± SD, mean ± standard deviation.

Two‐sided χ^2^ test and the student *t* test.

John Wiley & Sons, Ltd.

###### 

Primary information for *TCF7L2* rs7903146 C \> T, rs290481 T \> C, *INS* rs689 T \> A, and *INSR* rs1799817 G \> A polymorphisms

  Genotyped SNPs              Chromosome   Chr Pos (NCBI build 37)   Region      MAF[^a^](#jcb29167-tbl2-note-0002){ref-type="fn"} for Chinese in database (Hapmap‐CHB)   MAF in our controls (n = 1541)   *P* value for HWE[^b^](#jcb29167-tbl2-note-0003){ref-type="fn"} test in our controls   Genotyping method   Genotyping value (%)
  --------------------------- ------------ ------------------------- ----------- ---------------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------------------------------------------- ------------------- ----------------------
  *TCF7L2* rs7903146 C \> T   10           114758349                 Intron 4    0.03                                                                                     0.03                             .817                                                                                   SNPscan             99.07
  *TCF7L2* rs290481 T \> C    10           114923825                 Intron 13   0.41                                                                                     0.39                             .086                                                                                   SNPscan             99.20
  *INS* rs689 T \> A          11           2182224                   Intron 1    0.08                                                                                     0.04                             .355                                                                                   SNPscan             99.16
  *INSR* rs1799817 G \> A     19           7125297                   Exon17      0.42                                                                                     0.41                             .431                                                                                   SNPscan             99.16

Abbreviation: TCF7L2, transcription factor 7‐like 2.

MAF: minor allele frequency.

HWE: Hardy--Weinberg equilibrium.

John Wiley & Sons, Ltd.

3.2. Association of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms with AEG {#jcb29167-sec-0090}
------------------------------------------------------------------------------------------------------------

Table [3](#jcb29167-tbl-0003){ref-type="table"} summaries the genotype distribution of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms. Compared with the *TCF7L2* rs290481 TT genotype, TC and TC/CC genotypes might be associated with the risk of AEG (TC vs TT: crude *P* = .007 and TC/CC vs TT: crude *P* = .004 \[Table [4](#jcb29167-tbl-0004){ref-type="table"}\]). Additionally, compared with the *INSR* rs1799817 GG genotype, we found that *INSR* rs1799817 GA/AA genotypes increased the risk of AEG (GA/AA vs GG: crude *P* = .036 \[Table [4](#jcb29167-tbl-0004){ref-type="table"}\]). After adjustment for BMI, sex, alcohol use and smoking status, the significant association was not altered (Table [4](#jcb29167-tbl-0004){ref-type="table"}).

###### 

The frequencies of *TCF7L2* rs7903146 C \> T, rs290481 T \> C, *INS* rs689 T \> A, and *INSR* rs1799817 G \> A polymorphisms in different AEG subgroups

  Genotype                    Overall cases (n = 720)   Stage I/II patients (n = 211)   Stage III/IV patients (n = 509)   Controls (n = 1541)                        
  --------------------------- ------------------------- ------------------------------- --------------------------------- --------------------- ----- ------- ------ -------
  *TCF7L2* rs7903146 C \> T                                                                                                                                          
  CC                          666                       94.87                           193                               93.69                 473   95.36   1448   94.15
  CT                          35                        4.99                            12                                5.83                  23    4.64    88     5.72
  TT                          1                         0.14                            1                                 0.49                  0     0       2      0.13
  T allele                    37                        2.64                            14                                3.40                  23    2.32    92     2.99
  *TCF7L2* rs290481 T \> C                                                                                                                                           
  TT                          229                       32.48                           60                                29.13                 169   33.87   596    38.75
  TC                          372                       52.77                           116                               56.31                 256   51.30   697    45.32
  CC                          104                       14.75                           30                                14.56                 74    14.83   245    15.93
  C allele                    580                       41.13                           176                               42.72                 404   40.48   1187   38.59
  *INS* rs689 T \> A                                                                                                                                                 
  TT                          638                       90.50                           187                               90.78                 451   90.38   1411   91.80
  TA                          60                        8.51                            18                                8.74                  42    8.42    121    7.87
  AA                          7                         0.99                            1                                 0.49                  6     1.20    5      0.33
  A allele                    74                        5.25                            20                                4.85                  54    5.41    131    4.26
  *INSR* rs1799817 G \> A                                                                                                                                            
  GG                          215                       30.50                           67                                32.52                 148   29.66   538    35.00
  GA                          359                       50.92                           98                                47.57                 261   52.30   730    47.50
  AA                          131                       18.58                           41                                19.90                 90    18.04   269    17.50
  A allele                    621                       44.04                           180                               43.69                 441   44.19   1268   41.25

Abbreviations: AEG, esophagogastric junction; TCF7L2, transcription factor 7‐like 2.

John Wiley & Sons, Ltd.

###### 

Logistic regression analyses of association of *TCF7L2* rs7903146 C \> T, rs290481 T \> C, *INS* rs689 T \> A, and *INSR* rs1799817 G \> A polymorphisms with risk of AEG

  Genotype                    Overall patients (n = 720) vs controls (n = 1541)   Stage I/II patients (n = 211) vs controls (n = 1541)   Stage III/IV patients (n = 509) vs controls (n = 1541)                                                                                                                                                 
  --------------------------- --------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- ---------- ----------------------- ---------- ----------------------- ---------- ------------------------ ---------- ------------------------ ----------
  *TCF7L2* rs7903146 C \> T                                                                                                                                                                                                                                                                                                                     
  CT vs CC                    0.84 (0.56--1.26)                                   .408                                                   0.84 (0.56--1.27)                                        .410       1.00 (0.54--1.86)       .998       1.00 (0.54--1.87)       .991       0.78 (0.49--1.25)        .301       0.78 (0.48--1.25)        .298
  TT vs CC                    1.06 (0.10--11.72)                                  .962                                                   1.08 (0.10--12.11)                                       .951       3.67 (0.3340.60)        .290       4.14 (0.37--46.69)      .251       ...                      ...        ...                      ...
  CT/TT vs CC                 0.87 (0.59--1.29)                                   .491                                                   0.87 (0.58--1.30)                                        .493       1.08 (0.59--1.98)       .793       1.09 (0.60--2.00)       .773       0.78 (0.49--1.25)        .306       0.78 (0.49--1.25)        .301
  TT vs CC/CT                 1.10 (0.10--12.11)                                  .940                                                   1.13 (0.10--12.67)                                       .922       3.75 (0.34--41.50)      .282       4.30 (0.38--48.78)      .239       ...                      ...        ...                      ...
  *TCF7L2* rs290481 T \> C                                                                                                                                                                                                                                                                                                                      
  TC vs TT                    **1.31 (1.08--1.59)**                               **.007**                                               **1.31 (1.08--1.60)**                                    **.007**   **1.53 (1.11--2.12)**   **.009**   **1.53 (1.11--2.12)**   **.010**   1.23 (0.99--1.53)        .066       1.23 (0.98--1.53)        .074
  CC vs TT                    1.04 (0.79--1.37)                                   .768                                                   1.06 (0.80--1.39)                                        .699       1.13 (0.71--1.78)       .605       1.12 (0.71--1.78)       .621       1.01 (0.74--1.38)        .946       1.04 (0.76--1.42)        .809
  TC/CC vs TT                 **1.32 (1.09--1.59)**                               **.004**                                               **1.32 (1.09--1.60)**                                    **.004**   **1.54 (1.12--2.12)**   **.008**   **1.54 (1.12--2.12)**   **.008**   1.24 (1.00--1.53)        .051       1.24 (1.00--1.53)        .051
  CC vs. TT/TC                0.91 (0.71--1.17)                                   .475                                                   0.92 (0.72--1.19)                                        .536       0.90 (0.60--1.36)       .613       0.89 (0.59--1.35)       .593       0.92 (0.69--1.22)        .557       0.94 (0.71--1.26)        .694
  *INS* rs689 T \> A                                                                                                                                                                                                                                                                                                                            
  TA vs TT                    1.08 (0.78--1.48)                                   .663                                                   1.09 (0.79--1.52)                                        .589       1.10 (0.65--1.84)       .728       1.13 (0.67--1.91)       .636       1.07 (0.74--1.54)        .735       1.09 (0.75--1.59)        .635
  AA vs TT                    3.03 (0.96--9.58)                                   .059                                                   2.85 (0.89--9.13)                                        .078       1.48 (0.17--12.69)      .723       1.82 (0.21--15.77)      .587       **3.68 (1.12--12.13)**   **.032**   **3.43 (1.02--11.51)**   **.046**
  TA/AA vs TT                 1.18 (0.86--1.62)                                   .307                                                   1.19 (0.87--1.63)                                        .276       1.14 (0.69--1.89)       .617       1.19 (0.71--1.98)       .508       1.19 (0.84--1.69)        .324       1.21 (0.85--1.73)        .284
  AA vs. TT/TA                3.07 (0.98--9.70)                                   .056                                                   2.88 (0.90--9.21)                                        .075       1.50 (0.17--12.86)      .713       1.85 (0.21--16.08)      .575       **3.73 (1.13--12.27)**   **.030**   **3.45 (1.03--11.57)**   **.045**
  *INSR* rs1799817 G \> A                                                                                                                                                                                                                                                                                                                       
  GA vs GG                    1.16 (0.95--1.42)                                   .147                                                   1.16 (0.95--1.41)                                        .159       1.01 (0.73--1.40)       .949       1.02 (0.73--1.41)       .930       1.23 (0.98--1.54)        .078       1.22 (0.97--1.54)        .085
  AA vs GG                    1.15 (0.89--1.49)                                   .299                                                   1.15 (0.88--1.49)                                        .310       1.15 (0.76--1.73)       .512       1.16 (0.77--1.75)       .491       1.15 (0.85--1.55)        .364       1.14 (0.84--1.54)        .396
  GA/AA vs GG                 **1.23 (1.01--1.49)**                               **.036**                                               **1.23 (1.01--1.49)**                                    **.040**   1.12 (0.82--1.52)       .483       1.13 (0.83--1.54)       .453       **1.28 (1.03--1.59)**    **.028**   **1.27 (1.02--1.59)**    **.034**
  AA vs GG/GA                 1.08 (0.85--1.36)                                   .535                                                   1.08 (0.85--1.36)                                        .537       1.17 (0.81--1.69)       .398       1.18 (0.82--1.71)       .382       1.04 (0.80--1.35)        .784       1.03 (0.79--1.35)        .820

*Note*: Bold values are statistically significant (*P*\< .05).

Abbreviations: AEG, esophagogastric junction; CI, confidence interval; OR, odds ratio; TCF7L2, transcription factor 7--like 2.

Adjusted for age, sex, smoking status, alcohol use and BMI status.

John Wiley & Sons, Ltd.

We also conducted a subgroup analysis by different cancer stage. We identified that *TCF7L2* rs290481, *INS* rs689 and *INSR* rs1799817 SNPs increased the susceptibility of AEG in different cancer stage subgroups (*TCF7L2* rs290481; TC vs TT genetic model: adjusted *P* = .010; TC/CC vs TT genetic model: adjusted *P* = .008 for stage I/II subgroup; *INS* rs689; AA vs TT genetic model: adjusted *P* = .046; AA vs TT/TA genetic model: adjusted *P* = .045 for stage III/IV subgroup; *INSR* rs1799817; GA/AA vs GG genetic model: adjusted *P* = .034 for stage III/IV subgroup \[Table [4](#jcb29167-tbl-0004){ref-type="table"}\]).

However, the association between *TCF7L2* rs7903146 SNP and AEG risk was not found (Table [4](#jcb29167-tbl-0004){ref-type="table"}).

3.3. Association of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 loci with AEG in subgroups {#jcb29167-sec-0100}
----------------------------------------------------------------------------------------------------------------

The number of *TCF7L2* rs290481 genotype in different subgroups were shown in Table [5](#jcb29167-tbl-0005){ref-type="table"}. After logistic regression analysis, we found that *TCF7L2* rs290481 SNP was associated with the risk of AEG in male, \<64 years, ≥64 years, never smoking, never drinking, BMI \<24 kg/m^2^ and BMI ≥24 kg/m^2^ subgroups (Table [5](#jcb29167-tbl-0005){ref-type="table"}).

###### 

Stratified analyses between *TCF7L2* rs290481 T \> C polymorphism and AEG risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *TCF7L2* rs290481 T \> C (case/control)[^a^](#jcb29167-tbl5-note-0002){ref-type="fn"}   Adjusted OR [^b^](#jcb29167-tbl5-note-0003){ref-type="fn"} (95% CI); *P*                                                                                                                                            
  --------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------- ------ -------------------------------------------- ------------------------------- ------------------------------------------- -------------------------------
  Sex                                                                                                                                                                                                                                                                                                                               
  Male                  165/431                                                                                 287/511                                                                    72/192   1.00   **1.42 (1.12--1.78);** ***P*** ** = .003**   0.95 (0.69--1.32); *P* = .757   1.34 (1.07--1.68); *P* = .010               0.79 (0.59--1.06); *P* = .113
  Female                64/165                                                                                  85/186                                                                     32/53    1.00   1.04 (0.71--1.53); *P* = .834                1.42 (0.84--2.41); *P* = .192   1.25 (0.86--1.80); *P* = .241               1.45 (0.89--2.36); *P* = .134
  Age                                                                                                                                                                                                                                                                                                                               
  \<64                  103/289                                                                                 168/338                                                                    46/106   1.00   1.25 (0.93--1.67); *P* = .136                1.16 (0.76--1.76); *P* = .490   **1.34 (1.01--1.77);** ***P*** = **.046**   1.06 (0.72--1.54); *P* = .785
  ≥64                   126/307                                                                                 204/359                                                                    58/139   1.00   **1.35 (1.03--1.76);** ***P*** = **.030**    0.99 (0.68--1.43); *P* = .948   1.29 (1.00--1.67); *P* = .052               0.85 (0.60--1.18); *P* = .327
  Smoking status                                                                                                                                                                                                                                                                                                                    
  Never                 160/458                                                                                 277/542                                                                    75/194   1.00   **1.37 (1.09--1.72);** ***P*** = **.008**    1.02 (0.74--1.40); *P* = .916   **1.37 (1.10--1.71);** ***P*** = **.006**   0.87 (0.65--1.17); *P* = .356
  Ever                  69/138                                                                                  95/155                                                                     29/51    1.00   1.16 (0.78--1.71); *P* = .471                1.11 (0.64--1.93); *P* = .720   1.16 (0.80--1.69); *P* = .436               1.03 (0.62--1.72); *P* = .911
  Alcohol consumption                                                                                                                                                                                                                                                                                                               
  Never                 191/537                                                                                 315/614                                                                    88/224   1.00   **1.35 (1.10--1.67);** ***P*** = **.005**    1.04 (0.77--1.40); *P* = .811   **1.36 (1.10--1.66);** ***P*** = **.004**   0.89 (0.68--1.17); *P* = .413
  Ever                  38/59                                                                                   57/83                                                                      16/21    1.00   1.07 (0.62--1.84); *P* = .814                1.10 (0.50--2.44); *P* = .807   1.08 (0.64--1.82); *P* = .781               1.06 (0.52--2.20); *P* = .868
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                                                                     
  \<24                  152/318                                                                                 244/378                                                                    68/129   1.00   1.26 (0.98--1.61); *P* = .071                1.04 (0.73--1.47); *P* = .848   **1.29 (1.01--1.64);** ***P*** = **.040**   0.93 (0.68--1.28); *P* = .656
  ≥24                   77/278                                                                                  128/319                                                                    36/116   1.00   **1.41 (1.02--1.95);** ***P*** = **.038**    1.11 (0.71--1.74); *P* = .649   **1.38 (1.01--1.89);** ***P*** = **.042**   0.93 (0.62--1.39); *P* = .711

*Note*: Bold values are statistically significant (*P* \< .05). Abbreviations: AEG, esophagogastric junction; BMI, body mass index; CI, confidence interval; OR, odds ratio; TCF7L2, transcription factor 7--like 2.

For *TCF7L2* rs290481 T \> C, the genotyping was successful in 705 (97.92%) EGJA cases and 1538 (99.81%) controls.

Adjusted for multiple comparisons (age, sex, smoking status, BMI, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

John Wiley & Sons, Ltd.

After adjusting alcohol use, smoking status, sex, age, and BMI, the association of *INSR* rs1799817 SNP with the risk of AEG was found in male, \< 64 years, ever smoking and ever drinking subgroups (Table [6](#jcb29167-tbl-0006){ref-type="table"}).

###### 

Stratified analyses between *INSR* rs1799817 G \> A polymorphism and AEG risk by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *INSR* rs1799817 G \> A (case/control)[^a^](#jcb29167-tbl6-note-0002){ref-type="fn"}   Adjusted OR[^b^](#jcb29167-tbl6-note-0003){ref-type="fn"} (95% CI); *P*                                                                                                                                                        
  --------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------- --------- ------ ------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------
  Sex                                                                                                                                                                                                                                                                                                                                         
  Male                  154/406                                                                                269/544                                                                   101/183   1.00   1.24 (0.98--1.57); *P* = .075               **1.40 (1.03--1.90);** ***P*** =** .032**   **1.34 (1.06--1.68);** ***P*** =** .013**   1.25 (0.95--1.64); *P* = .111
  Female                61/132                                                                                 90/186                                                                    30/86     1.00   0.92 (0.62--1.35); *P* = .656               0.66 (0.39--1.10); *P* = .111               0.93 (0.64--1.35); *P* = .700               0.73 (0.46--1.16); *P* = .178
  Age                                                                                                                                                                                                                                                                                                                                         
  \<64                  84/251                                                                                 171/354                                                                   62/128    1.00   1.24 (0.91--1.68); *P* = .169               1.26 (0.85--1.86); *P* = .251               **1.38 (1.03--1.86);** ***P*** =** .034**   1.15 (0.81--1.61); *P* = .439
  ≥64                   131/287                                                                                188/376                                                                   69/141    1.00   1.06 (0.81--1.39); *P* = .690               1.04 (0.73--1.49); *P* = .820               1.09 (0.84--1.40); *P* = .533               1.02 (0.74--1.41); *P* = .891
  Smoking status                                                                                                                                                                                                                                                                                                                              
  Never                 159/405                                                                                259/570                                                                   94/218    1.00   1.07 (0.84--1.34); *P* = .597               1.01 (0.75--1.37); *P* = .939               1.13 (0.90--1.41); *P* = .296               1.00 (0.77--1.31); *P* = .986
  Ever                  56/133                                                                                 100/160                                                                   37/51     1.00   1.48 (0.98--2.23); *P* = .060               1.68 (0.98--2.88); *P* = .061               **1.57 (1.06--2.32);** ***P*** =** .024**   1.34 (0.83--2.16); *P* = .232
  Alcohol consumption                                                                                                                                                                                                                                                                                                                         
  Never                 186/466                                                                                298/665                                                                   110/243   1.00   1.03 (0.83--1.28); *P* = .784               1.05 (0.79--1.39); *P* = .749               1.11 (0.90--1.36); *P* = .345               1.06 (0.82--1.36); *P* = .669
  Ever                  29/72                                                                                  61/65                                                                     21/26     1.00   **2.39 (1.35--4.25);** ***P*** =** .003**   1.97 (0.94--4.14); *P* = .072               **2.31 (1.34--3.98);** ***P*** = **.003**   1.20 (0.62--2.32); *P* = .583
  BMI (kg/m2)                                                                                                                                                                                                                                                                                                                                 
  \<24                  135/277                                                                                243/400                                                                   86/147    1.00   1.17 (0.91--1.52); *P* = .226               1.12 (0.80--1.57); *P* = .504               1.25 (0.98--1.61); *P* = .077               1.05 (0.78--1.41); *P* = .755
  ≥24                   80/261                                                                                 116/330                                                                   45/122    1.00   1.11 (0.80--1.54); *P* = .522               1.18 (0.77--1.81); *P* = .437               1.17 (0.86--1.60); *P* = .313               1.13 (0.77--1.65); *P* = .528

*Note*: Bold values are statistically significant (*P* \< .05). Abbreviations: AEG, esophagogastric junction; BMI, body mass index; CI, confidence interval; OR, odds ratio.

For *INSR* rs1799817 G \> A, the genotyping was successful in 705 (97.92%) EGJA cases and 1537 (99.74%) controls.

Adjusted for multiple comparisons (age, sex, smoking status, BMI and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

John Wiley & Sons, Ltd.

3.4. Association between *TCF7L2* rs7903146, rs290481, *INS* rs689 and *INSR* rs1799817 loci, and lymph node status in AEG patients {#jcb29167-sec-0110}
-----------------------------------------------------------------------------------------------------------------------------------

Among the 720 AEG cases, there were 424 patients with lymphatic metastasis and 296 patients without lymphatic metastasis. There was null relationship of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 SNPs with different lymph node status (Table [7](#jcb29167-tbl-0007){ref-type="table"}).

###### 

Logistic regression analyses of the association between *TCF7L2* rs7903146 C \> T, rs290481 T \> C, *INS* rs689 T \> A, and *INSR* rs1799817 G \> A polymorphisms, and lymph node status in AEG patients

  Genotype                    Positive (n = 424)   Negative (n = 296)                                                                
  --------------------------- -------------------- -------------------- ----- ------- ------------------- ------ ------------------- ------
  *TCF7L2* rs7903146 C \> T                                                                                                          
  CC                          394                  95.17                272   94.44   1.00                       1.00                
  CT                          20                   4.83                 15    5.21    0.92 (0.47--1.84)   .822   0.95 (0.48--1.90)   .887
  TT                          0                    0.00                 1     0.35    ...                 ...    ...                 ...
  CT+TT                       20                   4.83                 16    5.56    0.86 (0.44--1.70)   .669   0.88 (0.45--1.75)   .720
  CC+CT                       414                  100                  287   99.65   1.00                       1.00                
  TT                          0                    0.00                 1     0.35    ...                 ...    ...                 ...
  *TCF7L2* rs290481 T \> C                                                                                                           
  TT                          127                  30.53                102   35.29   1.00                       1.00                
  TC                          225                  54.09                147   50.87   1.24 (0.89--1.71)   .204   1.26 (0.90--1.75)   .178
  CC                          64                   15.38                40    13.84   1.29 (0.81--2.06)   .284   1.30 (0.81--2.08)   .275
  TC+CC                       289                  69.47                187   64.71   1.24 (0.90--1.71)   .184   1.25 (0.91--1.72)   .177
  TT+TC                       352                  84.62                249   86.16   1.00                       1.00                
  CC                          64                   15.38                40    13.84   1.13 (0.74--1.74)   .570   1.13 (0.73--1.73)   .587
  *INS* rs689 T \> A                                                                                                                 
  TT                          375                  90.14                263   91.00   1.00                       1.00                
  TA                          36                   8.65                 24    8.30    1.06 (0.62--1.81)   .839   1.03 (0.60--1.78)   .915
  AA                          5                    1.20                 2     0.69    1.76 (0.34--9.15)   .500   1.75 (0.33--9.21)   .512
  TA+AA                       41                   9.86                 26    9.00    1.11 (0.66--1.85)   .702   1.08 (0.64--1.81)   .785
  TT+TA                       411                  98.80                287   99.31   1.00                       1.00                
  AA                          5                    1.20                 2     0.69    1.75 (0.34--9.06)   .507   1.74 (0.33--9.17)   .515
  *INSR* rs1799817 G \> A                                                                                                            
  GG                          123                  29.57                92    31.83   1.00                       1.00                
  GA                          221                  53.13                138   47.75   1.21 (0.86--1.70)   .267   1.19 (0.84--1.67)   .325
  AA                          72                   17.31                59    20.42   0.92 (0.60--1.42)   .713   0.92 (0.59--1.41)   .689
  GA+AA                       293                  70.43                197   68.17   1.11 (0.80--1.54)   .520   1.08 (0.78--1.51)   .628
  GG+GA                       344                  82.69                230   79.58   1.00                       1.00                
  AA                          72                   17.31                59    20.42   0.82 (0.56--1.20)   .297   0.82 (0.56--1.20)   .301

Abbreviations: AEG, esophagogastric junction; CI, confidence interval; OR, odds ratio; TCF7L2, transcription factor 7--like 2.

Adjusted for age, sex, smoking, alcohol use and BMI status.

John Wiley & Sons, Ltd.

3.5. Association of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 loci with the risk of lymph node metastasis in AEG patients in different stratification groups {#jcb29167-sec-0120}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After adjustment for risk factors, the results indicated that rs290481 SNP in *TCF7L2* gene increased the risk of lymph node metastasis in drinking AEG patients (TC vs TT genetic model: adjusted *P* = .047 (Table [8](#jcb29167-tbl-0008){ref-type="table"}\]).

###### 

Stratified analyses between *TCF7L2* rs290481 T \> C polymorphism and lymph node status in AEG patients by sex, age, BMI, smoking status, and alcohol consumption

  Variable              *TCF7L2* rs290481 T \> C (Positive/Negative)[^a^](#jcb29167-tbl8-note-0002){ref-type="fn"}   Adjusted OR[^b^](#jcb29167-tbl8-note-0003){ref-type="fn"} (95% CI); *P*                                                                                                                              
  --------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------- ------ ------------------------------------------- ------------------------------- ------------------------------- -------------------------------
  Sex                                                                                                                                                                                                                                                                                                                     
  Male                  88/77                                                                                        173/114                                                                   42/30   1.00   1.31 (0.89--1.94); *P* = .175               1.21 (0.69--2.12); *P* = .506   1.29 (0.89--1.88); *P* = .184   1.02 (0.62--1.70); *P* = .932
  Female                39/25                                                                                        52/33                                                                     22/10   1.00   1.02 (0.52--2.01); *P* = .952               1.50 (0.60--3.72); *P* = .387   1.14 (0.60--2.14); *P* = .697   1.48 (0.64--3.39); *P* = .358
  Age                                                                                                                                                                                                                                                                                                                     
  \<64                  61/42                                                                                        104/64                                                                    31/15   1.00   1.14 (0.68--1.90); *P* = .616               1.45 (0.69--3.04); *P* = .321   1.20 (0.74--1.96); *P* = .455   1.35 (0.69--2.64); *P* = .388
  ≥64                   66/60                                                                                        121/83                                                                    33/25   1.00   1.33 (0.85--2.10); *P* = .211               1.14 (0.61--2.15); *P* = .681   1.29 (0.84--1.98); *P* = .249   0.96 (0.54--1.69); *P* = .879
  Smoking status                                                                                                                                                                                                                                                                                                          
  Never                 90/70                                                                                        171/106                                                                   46/29   1.00   1.31 (0.88--1.95); *P* = .190               1.27 (0.72--2.24); *P* = .401   1.30 (0.89--1.91); *P* = .180   1.08 (0.65--1.79); *P* = .773
  Ever                  37/32                                                                                        54/41                                                                     18/11   1.00   1.11 (0.59--2.08); *P* = .748               1.42 (0.58--3.52); *P* = .444   1.17 (0.65--2.13); *P* = .598   1.34 (0.59--3.09); *P* = .487
  Alcohol consumption                                                                                                                                                                                                                                                                                                     
  Never                 108/83                                                                                       185/130                                                                   54/34   1.00   1.10 (0.77--1.59); *P* = .597               1.22 (0.73--2.05); *P* = .456   1.13 (0.79--1.60); *P* = .501   1.15 (0.72--1.83); *P* = .568
  Ever                  19/19                                                                                        40/17                                                                     10/6    1.00   **2.42 (1.01--5.78);** ***P*** =** .047**   1.84 (0.54--6.24); *P* = .331   2.27 (1.00--5.18); *P* = .051   1.10 (0.36--3.35); *P* = .872
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                                                           
  \<24                  89/63                                                                                        152/92                                                                    41/27   1.00   1.17 (0.77--1.77); *P* = .472               1.06 (0.59--1.91); *P* = .840   1.14 (0.77--1.70); *P* = .513   0.97 (0.57--1.64); *P* = .902
  ≥24                   38/39                                                                                        73/55                                                                     23/13   1.00   1.42 (0.79--2.53); *P* = .241               1.75 (0.76--4.03); *P* = .187   1.49 (0.86--2.58); *P* = .161   1.43 (0.67--3.07); *P* = .355

*Note*: Bold values are statistically significant (P \< .05). Abbreviations: AEG, esophagogastric junction; BMI, body mass index; CI, confidence interval; OR, odds ratio; TCF7L2, transcription factor 7--like 2.

For *TCF7L2* rs290481 T \> C, the genotyping was successful in 705 (97.92%) EGJA cases.

Adjusted for multiple comparisons (age, sex, smoking status, BMI and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

John Wiley & Sons, Ltd.

An association of *INSR* rs1799817 SNP with the risk of lymph node metastasis of patients with AEG was found in some subgroups (ever smoking subgroup: AA vs GG: adjusted *P* = .002; AA vs GG/GA: adjusted *P* = .001 and ever drinking subgroup: AA vs GG/GA: adjusted *P* = .030 \[Table [9](#jcb29167-tbl-0009){ref-type="table"}\]).

###### 

Stratified analyses between *INSR* rs1799817 G\> A polymorphism and lymph node status in AEG patients by sex, age, BMI, smoking status and alcohol consumption

  Variable              *INSR* rs1799817 G \> A (Positive/Negative) [^a^](#jcb29167-tbl9-note-0002){ref-type="fn"}   Adjusted OR [^b^](#jcb29167-tbl9-note-0003){ref-type="fn"} (95% CI); *P*                                                                                                                               
  --------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------- ------ -------------------------------- ------------------------------------------- ------------------------------- -------------------------------------------
  Sex                                                                                                                                                                                                                                                                                                                       
  Male                  88/66                                                                                        160/109                                                                    55/46   1.00   1.04 (0.69--1.56); *P*= .850     0.86 (0.52--1.43); *P* = .566               0.99 (0.67--1.45); *P* = .946   0.84 (0.54--1.30); *P* = .437
  Female                35/26                                                                                        61/29                                                                      17/13   1.00   1.59 (0.81--3.13); *P* = .180    0.96 (0.40--2.35); *P* = .936               1.40 (0.74--2.63); *P* = .305   0.74 (0.33--1.64); *P* = .452
  Age                                                                                                                                                                                                                                                                                                                       
  \<64                  50/34                                                                                        111/60                                                                     35/27   1.00   1.27 ( 0.73--2.21); *P* = .389   0.89 (0.45--1.76); *P* = .744               1.16 (0.68--1.96); *P* = .587   0.76 (0.43--1.33); *P* = .335
  ≥64                   73/58                                                                                        110/78                                                                     37/32   1.00   1.12 (0.71--1.77); *P* = .620    0.96 (0.53--1.73); *P* = .882               1.07 (0.70--1.65); *P* = .743   0.89 (0.53--1.52); *P* = .676
  Smoking status                                                                                                                                                                                                                                                                                                            
  Never                 87/72                                                                                        160/99                                                                     60/34   1.00   1.30 (0.87--1.95); *P* = .198    1.44 (0.85--2.44); *P* = .175               1.34 (0.91--1.96); *P* = .135   1.22 (0.77--1.95); *P* = .396
  Ever                  36/20                                                                                        61/39                                                                      12/25   1.00   0.83 (0.42--1.64); *P* = .587    **0.25 (0.10--0.61);** ***P*** =** .002**   0.60 (0.32--1.16); *P* = .127   **0.29 (0.13--0.61);** ***P*** =** .001**
  Alcohol consumption                                                                                                                                                                                                                                                                                                       
  Never                 103/83                                                                                       181/117                                                                    63/47   1.00   1.22 (0.84--1.77); *P* = .302    1.08 (0.67--1.74); *P* = .765               1.18 (0.83--1.68); *P* = .366   0.95 (0.63--1.45); *P* = .825
  Ever                  20/9                                                                                         40/21                                                                      9/12    1.00   0.86 (0.33--2.28); *P* = .764    0.30 (0.09--1.00); *P* = .050               0.65 (0.26--1.64); *P* = .364   **0.33 (0.12--0.90);** ***P*** =** .030**
  BMI (kg/m2)                                                                                                                                                                                                                                                                                                               
  \<24                  79/56                                                                                        151/92                                                                     52/34   1.00   1.17 (0.75--1.80); *P* = .491    1.08 (0.62--1.88); *P* = .794               1.14 (0.75--1.73); *P* = .531   0.98 (0.60--1.58); *P* = .919
  ≥24                   44/36                                                                                        70/46                                                                      20/25   1.00   1.26 (0.70--2.27); *P* = .432    0.69 (0.33--1.45); *P* = .331               1.06 (0.62--1.84); *P* = .828   0.60 (0.31--1.17); *P* = .133

*Note*: Bold values are statistically significant (P \< .05). Abbreviations: AEG, esophagogastric junction; BMI, body mass index; CI, confidence interval; OR, odds ratio.

For *INSR* rs1799817 G \> A, the genotyping was successful in 705 (97.92%) EGJA cases.

Adjusted for multiple comparisons (age, sex, smoking status, BMI and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

John Wiley & Sons, Ltd.

The correlation between *TCF7L2* rs7903146 and *INS* rs689 polymorphisms and lymph node metastasis in patients with AEG was not found in different stratification groups (data were not shown).

4. DISCUSSION {#jcb29167-sec-0130}
=============

It is believed that elevated ratio of obesity and overweight may be associated with an increasing of AEG.[5](#jcb29167-bib-0005){ref-type="ref"} *TCF7L2*, *INS,* and *INSR* gene may be implicated in the development of obesity and overweight. Here, we studied the potential relationships of *TCF7L2* rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms with AEG susceptibility. Finally, we found that *TCF7L2* rs290481, *INS* rs689, and *INSR* rs1799817 polymorphisms might be associated with the increased susceptibility of AEG. In addition, we found that *TCF7L2* rs290481 and *INSR* rs1799817 SNPs might influence the lymph node metastasis in patients with AEG in some subgroups.

*TCF7L2* rs290481 (T \> C) locus is located in intron 13 (NC_000010.10:g.114923825C \> T). Zhu et al[26](#jcb29167-bib-0026){ref-type="ref"} reported that rs290481 polymorphism in *TCF7L2* gene increased the susceptibility of T2D and linked to the level of fasting glucose. A previous study evaluated the potential association between *TCF7L2* rs290481 variants and cancer risk in Chinese patients with T2D. It is observed that *TCF7L2* rs290481 polymorphism was positively associated with cancer susceptibility under the additive model.[27](#jcb29167-bib-0027){ref-type="ref"} The previous report showed that *TCF7L2* rs290481 might influence the risik of HCC.[14](#jcb29167-bib-0014){ref-type="ref"} Individuals carrying C~rs290481~C~rs290487~A~rs290489~ haplotype might have a significantly higher HCC susceptibility than those with T~rs290481~T~rs290487~G~rs290489~.[14](#jcb29167-bib-0014){ref-type="ref"} In this SNP, we found that the rs290481TC and TC/CC genotype of *TCF7L2* gene is relevant to increased susceptibility and progress of AEG. In additional, we also found that the potential association was more significant in BMI ≥24 kg/m^2^, which was in line with the findings of those studies mentioned above.[14](#jcb29167-bib-0014){ref-type="ref"}, [26](#jcb29167-bib-0026){ref-type="ref"}, [27](#jcb29167-bib-0027){ref-type="ref"}

In this study, the relationship between rs1799817 G \> A (NM_000208.2:c.3255C \> T) polymorphism in the *INSR* gene and AEG risk was also explored. We found that *INSR* rs1799817 G \> A polymorphism might confer the risk to AEG. However, we found *INSR* rs1799817 G \> A SNP might improve the progress of AEG. Maybe this polymorphism plays different role in different phases of AEG. Our results were similar to a previous study suggesting a positive association between the *INSR* rs1799817 locus and colorectal cancer in the female.[22](#jcb29167-bib-0022){ref-type="ref"} In this study, compared with *INSR* rs1799817 GG genotype, rs1799817 AA/GA genotype increased 1.23‐fold risk of AEG. We first investigated the relationship between the *INSR* rs1799817 polymorphism and the risk of AEG. Since the functional consequence of *INSR* rs1799817 G \> A polymorphism is a synonymous codon (<https://www.ncbi.nlm.nih.gov/snp/?term=rs1799817>), indicating that it could not change the primary structure of the INSR protein, the potential biological mechanism for this SNP altering the susceptibility for AEG is largely unknown. However, exon 17 of the *INSR* gene encodes the sequence of the tyrosine kinase domain, which plays a vital role in the function of INSR protein. Although *INSR* rs1799817 G \> A polymorphism is a coding‐synonymous variant, it is proposed that a G → A nucleotide substitution in this locus may influence the expression of INSR molecule by altering mRNA processing or translation. For these possible reasons, rs1799817 G \> A polymorphism may be a functional variant for *INSR* gene.

Sokhi et al[28](#jcb29167-bib-0028){ref-type="ref"} reported that *INS* rs689 polymorphism was associted with an increased risk of T2D. In addition, Lempainen et al[29](#jcb29167-bib-0029){ref-type="ref"} found that this polymorphism, cooperated with *PTPN22* rs2476601 and *IFIH1* rs1990760 loci, might be correlated with the β‐cell autoantibodies. A previous study has focused on the association of *INS* rs689 polymorphism with the risk of colorectal cancer.[22](#jcb29167-bib-0022){ref-type="ref"} However, the null association was found for *INS* rs689 polymorphism to colorectal cancer. In the present study, a tendency of increased risk to AEG was found in overall comparison. In a subgroup analysis, this association was more significant in stage III/IV subgroup compared with controls. In the future, the relationship of *INS* rs689 T \> A polymorphism with cancer risk should be explored in more case‐control studies.

Although well designed, the present study has some potential limitations and they should be taken into account when interpreted our findings. First, the included sample size was modest, which limited drawing strong conclusions and performing more detailed analyses. Second, we only studied four loci in these genes, the coverage could be insufficient. In the future, a tagging SNP study should be conducted. Third, for lack of the levels of serum proinsulin, insulin, glucagon and so on, we could not carry out further analysis on the association of these SNPs with the biochemistry characteristics. Finally, a functional study is needed to explain the mechanism of these identified SNPs.

In summary, this is the first study to explore the possible correlation between rs7903146 and rs290481, *INS* rs689 and *INSR* rs1799817 polymorphisms and the development of AEG. Our findings highlight that *TCF7L2* rs290481, *INS* rs689, and *INSR* rs1799817 polymorphisms may increase the risk of AEG. In addition, *TCF7L2* rs290481 and *INSR* rs1799817 SNPs may influence the lymph node metastasis in AEG patients.
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